• Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise.
• The company introduces a new RNAi manufacturing platform aimed at supporting its growing portfolio of RNA targeted medicines.
• Alnylam enters new industry partnerships that expand its presence across RNA therapeutics and drug discovery.

For investors watching RNA based medicines, Alnylam sits at the center of a maturing part of biotech with an approved TTR franchise and a growing commercial footprint. The shift to full year profitability adds a new dimension to the story, as the company now pairs a commercial revenue base with a broader RNAi platform and manufacturing capabilities.

Looking ahead, the combination of internal platform development and external partnerships could influence how Alnylam allocates capital between R&D, manufacturing and potential new indications. For investors, the key questions include how durable the TTR franchise proves to be and how effectively the company turns its RNAi expertise into a broader, sustainable product lineup.

Stay updated on the most important news stories for Alnylam Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alnylam Pharmaceuticals.

Alnylam’s first full year of profitability, with 2025 net income of US$313.75 million on revenue of US$3.71b, shows that its RNAi model is starting to scale commercially rather than relying only on upfronts and milestones. For you as an investor, that matters because it suggests the TTR franchise, including Amvuttra’s expanded ATTR-CM indication, is now big enough to cover a still-heavy R&D bill while funding a broader RNA-targeted portfolio. The new RNAi manufacturing platform points to a push for more control over cost of goods and capacity, which can be important if volumes rise or if pricing pressure builds across rare disease drugs.

How This Fits Into The Alnylam Pharmaceuticals Narrative

• The step into full-year profitability alongside strong TTR contribution aligns with the narrative that growing adoption of core RNAi therapies and operational leverage can support revenue growth and margin improvement.
• At the same time, the earnings mix reinforces how dependent Alnylam still is on a single franchise, which ties back to concerns about revenue concentration and potential margin pressure if competition in TTR amyloidosis intensifies.
• The move to a new RNAi manufacturing platform and emerging partnerships around RNA-targeted medicines extends the story into manufacturing efficiency and non-liver applications, which are not fully reflected in the original focus on cardiomyopathy launches and near-term rare disease assets.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Alnylam Pharmaceuticals to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Heavy reliance on the TTR franchise means setbacks in ATTR-CM or competing approaches from peers in rare disease and cardiology could hit revenue and profitability disproportionately.
• ⚠️ Continued high R&D and commercial spending, plus a US$2.26b shelf registration, points to ongoing capital needs that could lead to share issuance or pressure on returns if new programs do not scale as planned.
• 🎁 First-time profitability, with quarterly revenue of US$1.10b and a swing from a US$83.76 million loss to US$111.54 million net income, shows the existing portfolio can fund further RNAi development.
• 🎁 New RNA-focused partnerships and a dedicated RNAi manufacturing platform may widen Alnylam’s opportunity set versus other RNA and rare disease players such as Ionis Pharmaceuticals and Moderna by supporting new indications and potentially more efficient production.

What To Watch Going Forward

From here, you may want to watch how much of Alnylam’s revenue and profit growth continues to come from Amvuttra and the broader TTR franchise versus newer programs, including any RNA-targeted small-molecule collaborations. Progress on the new manufacturing platform will be worth tracking, especially if management starts to quantify cost savings or capacity gains. It is also useful to keep an eye on how large-cap rivals in RNA and cardiometabolic disease position their own therapies, as competitive outcomes could influence pricing, access and the durability of Alnylam’s earnings profile.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Alnylam Pharmaceuticals, head to the community page for Alnylam Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.